This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cometta, A.
Right arrow Articles by Glauser, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cometta, A.
Right arrow Articles by Glauser, M. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1996, 1108-1115, Vol 40, No. 5
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program

A Cometta, T Calandra, H Gaya, SH Zinner, R de Bock, A Del Favero, G Bucaneve, F Crokaert, WV Kern, J Klastersky, I Langenaeken, A Micozzi, A Padmos, M Paesmans, C Viscoli and MP Glauser
Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Combinations of beta-lactams plus aminoglycosides have been standard therapy for suspected infections in granulocytopenic cancer patients, especially those with profound long-lasting granulocytopenia. With the advent of new broad-spectrum bactericidal antibiotics such as extended- spectrum cephalosporins or carbapenems, the need to combine beta- lactams with aminoglycosides became more controversial. The objective of this prospective randomized multicenter study was to compare the efficacy, safety, and tolerance of meropenem monotherapy with those of the combination of ceftazidime plus amikacin for the empirical treatment of fever in granulocytopenic cancer patients. Of 1,034 randomized patients, 958 were assessable in the intent-to-treat analysis for response to antibacterial therapy, including 483 in the meropenem group and 475 in the ceftazidime-plus-amikacin group. The median durations of neutropenia were 16 and 17 days, respectively. A successful outcome was reported in 270 of 483 (56%) patients treated with monotherapy compared with 245 of 475 (52%) patients treated with the combination group (P = 0.20). The success rates in the monotherapy group and the combination group were similar by type of infection (single gram-negative bacteremia, single gram-positive bacteremia, clinically documented infection, and possible infection). The occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups (12% in both groups). Mortality due to the presenting infection or further infection was relatively low (8 patients treated with the monotherapy compared with 13 patients treated with the combination). A total of 1,027 patients were evaluable for adverse events; the proportion of those who developed adverse effects was similar between the two groups (29% in both groups), and only 19 (4%) patients in the monotherapy group and 31 (6%) in the combination group experienced an adverse event related or probably related to the study drug. Allergic reactions were the only reason for stopping the protocol antibiotic(s) (3 and 5 patients, respectively). This study confirms that monotherapy with meropenem is as effective as the combination of ceftazidime plus amikacin for the empiric treatment of fever in persistently granulocytopenic cancer patients, and both regimens were well tolerated.


This article has been cited by other articles:

  • Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D'Antonio, D., Buelli, M., Nosari, A. M., Cilloni, D., Zuffa, E., Cantaffa, R., Specchia, G., Amadori, S., Fabbiano, F., Deliliers, G. L., Lauria, F., Foa, R., Del Favero, A., the Gruppo Italiano Malattie Ematologiche dell'Adu, (2005). Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. NEJM 353: 977-987 [Abstract] [Full Text]  
  • Paul, M., Borok, S., Fraser, A., Vidal, L., Leibovici, L. (2005). Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55: 436-444 [Abstract] [Full Text]  
  • Sanz, M. A., Lopez, J., Lahuerta, J. J., Rovira, M., Batlle, M., Perez, C., Vazquez, L., Julia, A., Palau, J., Gutierrez, M., Capote, F. J., Ramos, F., Benlloch, L., Larrea, L., Jarque, I., for the Spanish PETHEMA Group, (2002). Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 50: 79-88 [Abstract] [Full Text]  
  • Eggimann, P., Pittet, D. (2001). Infection Control in the ICU. Chest 120: 2059-2093 [Abstract] [Full Text]  
  • Fleischhack, G., Hartmann, C., Simon, A., Wulff, B., Havers, W., Marklein, G., Hasan, C., Bode, U. (2001). Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 47: 841-853 [Abstract] [Full Text]  
  • Alcaide, F., Benitez, M. A., Carratala, J., Gudiol, F., Linares, J., Martin, R. (2001). In Vitro Activities of the New Ketolide HMR 3647 (Telithromycin) in Comparison with Those of Eight Other Antibiotics against Viridans Group Streptococci Isolated from Blood of Neutropenic Patients with Cancer. Antimicrob. Agents Chemother. 45: 624-626 [Abstract] [Full Text]  
  • Giamarellou, H., Bassaris, H. P., Petrikkos, G., Busch, W., Voulgarelis, M., Antoniadou, A., Grouzi, E., Zoumbos, N. (2000). Monotherapy with Intravenous Followed by Oral High-Dose Ciprofloxacin versus Combination Therapy with Ceftazidime plus Amikacin as Initial Empiric Therapy for Granulocytopenic Patients with Fever. Antimicrob. Agents Chemother. 44: 3264-3271 [Abstract] [Full Text]  
  • Feld, R., DePauw, B., Berman, S., Keating, A., Ho, W. (2000). Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. JCO 18: 3690-3698 [Abstract] [Full Text]  
  • Hoffken, G., Pasold, R., Pfluger, K. H., Finke, J., Fauser, A. A., Szelenyi, H., Wagner, J. (1999). An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. J Antimicrob Chemother 44: 367-376 [Abstract] [Full Text]  
  • Kern, W. V., Cometta, A., de Bock, R., Langenaeken, J., Paesmans, M., Gaya, H., Zanetti, G., Calandra, T., Glauser, M. P., Crokaert, F., Klastersky, J., Skoutelis, A., Bassaris, H., Zinner, S. H., Viscoli, C., Engelhard, D., Padmos, A., The International Antimicrobial Therapy Cooperativ, (1999). Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy. NEJM 341: 312-318 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»